[Pharmacokinetic comparison of two ozagrel polymorph forms in SD rats]

Area of Science:

• Pharmaceutical Sciences
• Drug Development
• Pharmacokinetics

Background:

• Ozagrel is a drug used for its therapeutic effects.
• Polymorphism, the ability of a solid material to exist in multiple crystalline forms, can significantly impact drug bioavailability and efficacy.
• Understanding the pharmacokinetic differences between ozagrel polymorphs is crucial for optimizing drug quality and therapeutic outcomes.

Purpose of the Study:

• To investigate the bioavailability differences between ozagrel polymorphs.
• To compare the pharmacokinetic profiles of different ozagrel solid forms.
• To provide insights for quality control in ozagrel drug production.

Main Methods:

• Oral administration of solid ozagrel in different polymorph forms to Sprague-Dawley (SD) rats.
• Establishment of a High-Performance Liquid Chromatography (HPLC) method for determining plasma ozagrel levels.
• Calculation and comparison of bioavailability and pharmacokinetic parameters (Cmax, AUC0-t, t½).

Main Results:

• No significant differences in overall pharmacokinetic parameters were observed between ozagrel Form I and Form II.
• The half-life (t½) of ozagrel Form II was significantly longer (4.73 ± 3.00 h) compared to Form I (1.53 ± 0.51 h).
• Peak plasma concentration (Cmax) and area under the curve (AUC0-t) showed comparable values between the two forms.

Conclusions:

• While overall pharmacokinetics are similar, the prolonged half-life of ozagrel Form II suggests potential for extended clinical action.
• Ozagrel Form II may be advantageous for pharmaceutical products requiring sustained drug release.
• These findings support the importance of polymorph characterization for effective quality control in ozagrel manufacturing.